Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells
Chimeric antigen receptor (CAR)-modified T cells have garnered substantial attention due to their clinical success, culminating in six Food and Drug Administration-approved therapies for hematological malignancies. Notably, CD19-specific CAR T cell therapies have achieved remarkable clinical efficac...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Taylor & Francis Group
2026-12-01
|
| Ráidu: | mAbs |
| Fáttát: | |
| Liŋkkat: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2602989 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|